Modeled CA-125 elimination rate constant K (KELIM), Hyperthermic intraperitoneal chemotherapy (HIPEC), Ovarian cancer, Chemotherapy response, Predictive biomarker
Endometrial cancer, immune checkpoint inhibitors, mismatch repair, prognosis, survival
Ovarian Neoplasms, Platinum-resistant, BRCA wild type, PARP inhibitor, Immunotherapy
Ovarian cancer, PARP inhibitor, Prognosis, recurrence, Survival
endometrial cancer, Lynch syndrome, microsatellite instability, mismatch repair
Uterine Cervical Neoplasms, Oligometastasis, Stereotactic Ablative Body Radiotherapy, Programmed Cell Death Ligand 1